Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Vivos Therapeutics (VVOS) Income from Continuing Operations (2020 - 2025)

Vivos Therapeutics' Income from Continuing Operations history spans 6 years, with the latest figure at 6954000.0 for Q4 2025.

  • Quarterly results put Income from Continuing Operations at 6954000.0 for Q4 2025, down 145.99% from a year ago — trailing twelve months through Dec 2025 was 21231000.0 (down 90.65% YoY), and the annual figure for FY2025 was 21230000.0, down 90.64%.
  • Income from Continuing Operations for Q4 2025 was 6954000.0 at Vivos Therapeutics, down from 5400000.0 in the prior quarter.
  • In the past five years, Income from Continuing Operations ranged from a high of 17856000.0 in Q4 2022 to a low of 6992000.0 in Q2 2022.
  • The 5-year median for Income from Continuing Operations is 3953500.0 (2021), against an average of 2291600.0.
  • Peak annual rise in Income from Continuing Operations hit 306.13% in 2021, while the deepest fall reached 197.29% in 2021.
  • Year by year, Income from Continuing Operations stood at 12914000.0 in 2021, then skyrocketed by 38.27% to 17856000.0 in 2022, then tumbled by 123.85% to 4259000.0 in 2023, then skyrocketed by 33.62% to 2827000.0 in 2024, then tumbled by 145.99% to 6954000.0 in 2025.
  • According to Business Quant data, Income from Continuing Operations over the past three periods came in at 6954000.0, 5400000.0, and 5013000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.